Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβA. Mishra(Linköping University), Charlotta Dabrosin(Linköping University)OncotargetJuly 28, 201610.18632/oncotarget.10871Cited by 48SaveCiteExport RISWatch citationsRelated PapersFulvestrant-Mediated Attenuation of the Innate Immune Response Decreases ER+ Breast Cancer Growth <i>In Vivo</i> More Effectively than Tamoxifen|Cancer Research|2020|21